MBOT trades 395.5% below Wall Street's consensus target of $5.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes MBOT achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 3 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, Microbot Medical Inc. (MBOT) has a Wall Street consensus price target of $5.50, based on estimates from 3 covering analysts. With the stock currently trading at $1.11, this represents a potential upside of +395.5%. The company has a market capitalization of $51M.
Analyst price targets range from a low of $5.50 to a high of $5.50, representing a 0% spread in expectations. The median target of $5.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 2 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, MBOT trades at a trailing P/E of -4.6x. Analysts expect EPS to grow -38.4% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 SSYSStratasys Ltd. | $557M | $6.42 | $12.50 | +94.7% | Buy | 58.4x | 36 |
 RBOTVicarious Surgical Inc. | $9716 | $0.00 | — | — | — | — | — |
 TRVITrevi Therapeutics, Inc. | $2.0B | $14.33 | $29.67 | +107.0% | Buy | — | 18 |
 ISRGIntuitive Surgical, Inc. | $160.0B | $452.80 | $485.44 | +7.2% | Buy | 40.3x | 57 |
 NVCRNovocure Ltd | $1.5B | $13.28 | $26.00 | +95.8% | Buy | — | 15 |
 MDTMedtronic plc | $130.7B | $101.80 | $97.73 | -4.0% | Buy | 17.0x | 51 |
 SYKStryker Corporation | $124.9B | $325.87 | $354.47 | +8.8% | Buy | 22.0x | 52 |
 BSXBoston Scientific Corporation | $63.5B | $42.75 | $54.65 | +27.8% | Buy | 13.5x | 44 |
 ABTAbbott Laboratories | $191.5B | $109.93 | $121.36 | +10.4% | Buy | 19.9x | 43 |
 ZBHZimmer Biomet Holdings, Inc. | $20.4B | $105.59 | $109.11 | +3.3% | Hold | 12.4x | 42 |
Quick answers to the most common questions about buying MBOT stock.
The consensus Wall Street price target for MBOT is $5.5, representing 395.5% upside from the current price of $1.11. With 3 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
MBOT has a consensus rating of "Buy" based on 3 Wall Street analysts. The rating breakdown is predominantly bullish, with 2 Buy/Strong Buy ratings. The consensus 12-month price target of $5.5 implies 395.5% upside from current levels.
MBOT's current price is $1.11 with a consensus target of $5.5 (395.5% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $5.5 for MBOT, while the most conservative target is $5.5. The consensus of $5.5 represents the median expectation. These targets typically reflect 12-month expectations.
MBOT is lightly followed, with 3 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month MBOT stock forecast based on 3 Wall Street analysts shows a consensus price target of $5.5, with estimates ranging from $5.5 (bear case) to $5.5 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on MBOT, with a "Buy" consensus rating and $5.5 price target (395.5% upside). 2 of 3 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
MBOT analyst price targets range from $5.5 to $5.5, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $5.5 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.